-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RAVrctDfYJlTv4c/88TzMoyglfc9yphPHHPYb6rcPTIomkbZ8PLUX50bA7QrIrgm nT2A5fFAdg7z5pYf66H0zQ== 0000891836-03-000545.txt : 20030919 0000891836-03-000545.hdr.sgml : 20030919 20030919170441 ACCESSION NUMBER: 0000891836-03-000545 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020331 FILED AS OF DATE: 20030919 EFFECTIVENESS DATE: 20030919 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 03903087 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 sc0282.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2002 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- -------------------------------------------- Form 13F File Number: 28-____________ The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. September 19, 2003 - --------------------- -------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [x] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ------------------ Form 13F Information Table Entry Total: 14 ------------------ Form 13F Information Table Entry Value: 233,205 ------------------ (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER NAME OF ISSUER TITLE OF CLASS CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS - -------------- -------------- ----- ------- ------- --- ---- ---------- -------- Autoimmune COM 052776101 29 26,100 SH SOLE Aclara Biosciences COM 00461P106 77 23,199 SH SOLE Arena Pharmaceuticals COM 040047102 306 30,700 SH SOLE Incyte COM 45337C102 6,448 541,810 SH SOLE Intrabiotics Pharmaceuticals COM 46116T506 2,258 645,140 SH SOLE Kosan Biosciences COM 50064W107 1,161 150,800 SH SOLE Neurogen COM 64124E106 8,211 643,500 SH SOLE Pharmacyclics COM 716933106 265 34,000 SH SOLE QLT COM 746927102 496 29,100 SH SOLE Regeneron Pharmaceuticals COM 75886F107 71,505 2,861,330 SH SOLE Third Wave Technologies COM 88428W108 125 37,200 SH SOLE Trimeris COM 896263100 75,019 1,736,550 SH SOLE Incyte Notes 5.5% 3/01/2007 CONV BONDS 45337CAC6 39,250 5,000,000 PRN SOLE Regeneron Pharmaceuticals Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAB3 28,055 25,275,000 PRN SOLE ------- 233,205 =======
COLUMN 8 VOTING AUTHORITY NAME OF ISSUER SOLE SHARED NONE - -------------- ---- ------ ---- Autoimmune 26,100 Aclara Biosciences 23,199 Arena Pharmaceuticals 30,700 Incyte 541,810 Intrabiotics Pharmaceuticals 645,140 Kosan Biosciences 150,800 Neurogen 643,500 Pharmacyclics 34,000 QLT 29,100 Regeneron Pharmaceuticals 2,861,330 Third Wave Technologies 37,200 Trimeris 1,736,550 Incyte Notes 5.5% 3/01/2007 5,000,000 Regeneron Pharmaceuticals Conv Notes 5.5% 10/17/08 (144A) 25,275,000
-----END PRIVACY-ENHANCED MESSAGE-----